Athira Pharma
Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.
Facts
- HQ
- Seattle
- Sectors
- Biopharmaceuticals, Biotech, Pharmaceuticals
- Employees
- 30
- Stage
- Series B
Is this your organization? Claim it
Members see Athira Pharma's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer